Patents by Inventor Izidore Lossos

Izidore Lossos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11311537
    Abstract: The present disclosure relates, in general, a method of diagnosing and treatment of lymphoproliferative disorders.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: April 26, 2022
    Assignee: UNIVERSITY OF MIAMI
    Inventors: Izidore Lossos, Ramiro E. Verdun
  • Publication number: 20200022979
    Abstract: The present disclosure relates, in general, a method of diagnosing and treatment of lymphoproliferative disorders.
    Type: Application
    Filed: October 26, 2017
    Publication date: January 23, 2020
    Inventors: Izidore Lossos, Ramiro E. Verdun
  • Patent number: 9447160
    Abstract: The present invention is directed to fusion proteins having an IL-21 cytokine portion and an anti-CD20 antibody portion, and methods of using such fusion proteins. The invention also provides pharmaceutical compositions and kits utilizing the IL-21-anti-CD20 fusion proteins. In particular, the methods, kits and compositions of the invention are useful in the treatment of cancer and autoimmune diseases.
    Type: Grant
    Filed: January 18, 2013
    Date of Patent: September 20, 2016
    Assignee: UNIVERSITY OF MIAMI
    Inventors: Izidore Lossos, Shruti Bhatt, Joseph Rosenblatt, Seung-Uon Shin
  • Patent number: 9358231
    Abstract: The present invention relates to novel compounds which are able to modulate b-raf kinases, and the use of such compounds in the treatment of various diseases, disorders or conditions.
    Type: Grant
    Filed: November 24, 2014
    Date of Patent: June 7, 2016
    Assignees: Dana-Farber Cancer Institute, Inc., University of Miami
    Inventors: Nathanael Gray, Hwan Geun Choi, Xianming Deng, Jianming Zhang, Izidore Lossos
  • Publication number: 20150157629
    Abstract: The present invention relates to novel compounds which are able to modulate b-raf kinases, and the use of such compounds in the treatment of various diseases, disorders or conditions.
    Type: Application
    Filed: November 24, 2014
    Publication date: June 11, 2015
    Applicants: Dana-Farber Cancer Institute, Inc., University of Miami
    Inventors: Nathanael Gray, Hwan Geun Choi, Xianming Deng, Jianming Zhang, Izidore Lossos
  • Publication number: 20150044134
    Abstract: The present invention is directed to fusion proteins having an IL-21 cytokine portion and an anti-CD20 antibody portion, and methods of using such fusion proteins. The invention also provides pharmaceutical compositions and kits utilizing the IL-21-anti-CD20 fusion proteins. In particular, the methods, kits and compositions of the invention are useful in the treatment of cancer and autoimmune diseases.
    Type: Application
    Filed: January 18, 2013
    Publication date: February 12, 2015
    Applicant: UNIVERSITY OF MIAMI
    Inventors: Izidore Lossos, Shruti Bhalt, Joseph Rosenblatt, Seung-Uon Shin
  • Publication number: 20110201008
    Abstract: Assays, methods and kits for predicting survival outcome in a subject having diffuse large B-cell lymphoma (DLBCL) and for measuring a subject's response to DLBCL therapy involve specific miRNAs that are prognostic biomarkers for prediction of outcome of DLBCL patients. Expression of miRNAs miR-18a, miR-181a and miR-222 is associated with response to therapy and outcome of patients with DLBCL. Measurement of these miRs can be used to identify patients' outcomes in the clinic and allow tailoring of patient-specific therapy.
    Type: Application
    Filed: December 1, 2010
    Publication date: August 18, 2011
    Applicant: UNIVERSITY OF MIAMI
    Inventors: Izidore Lossos, Alvero Alencar, Raquel Malumbres, Robert Tibshirani
  • Publication number: 20070026453
    Abstract: Methods and kits for classifying patients having diffuse large B-cell lymphoma (DLBCL) based upon expression of a plurality of genes are disclosed. Real-time quantitative RT-PCR can be used to measure expression values. Correlating expression values of the plurality of genes in a tumor sample from the patient to reference expression values obtained from DLBCL patients can stratify patients in the classification groups. The methods and kits can be used to predict overall patient survival.
    Type: Application
    Filed: October 3, 2006
    Publication date: February 1, 2007
    Inventors: Ronald Levy, Mark Wechser, Izidore Lossos, Robert Tibshirani, Ash Alizadeh, David Botstein
  • Publication number: 20050079513
    Abstract: Methods and kits for classifying patients having diffuse large B-cell lymphoma (DLBCL) based upon expression of a plurality of genes are disclosed. Real-time quantitative RT-PCR can be used to measure expression values. Correlating expression values of the plurality of genes in a tumor sample from the patient to reference expression values obtained from DLBCL patients can stratify patients in the classification groups. The methods and kits can be used to predict overall patient survival.
    Type: Application
    Filed: March 3, 2004
    Publication date: April 14, 2005
    Inventors: Ronald Levy, Mark Wechser, Izidore Lossos, Robert Tibshirani, Ash Alizadeh, David Botstein